Business Wire

Lazard and Arini Enter Cooperation and Sourcing Agreement for EMEA Private Credit

Share

Lazard, Inc. (NYSE: LAZ), a global financial advisory and asset management firm, and Arini Capital Management (“Arini”), a leading alternative credit manager, today announced an alliance focused on direct lending solutions for borrowers across EMEA.

The alliance further expands Lazard’s leading debt advisory and capital solutions services across EMEA and will provide Lazard’s corporate and sponsor advisory clients access to a potential new source of flexible financing solutions. Lazard Asset Management also will have the ability to introduce its clients to this unique private credit strategy.

The alliance will provide Arini access to Lazard’s origination activities for mid-cap borrowers across the EMEA region, subject to Lazard duties and client consent conditions, and is a key component of the launch of Arini’s European Direct Lending strategy. Arini Direct Lending will be focused on providing direct lending solutions across the European middle market and builds on the firm’s strong track record across European credit markets. Arini’s Europe-focused direct lending fund is expected to be anchored by British Columbia Investment Management Corporation (BCI) and additional institutional investors.

“Lazard is recognized for our trusted insights to support clients across Advisory and Asset Management in their most strategic initiatives and financial decisions,” said Peter R. Orszag, Lazard’s CEO and Chairman. “This relationship with Arini embodies our commitment to provide clients with relevant, differentiated solutions and is in support of the firm’s long-term objectives as outlined in Lazard 2030.”

“Arini has deep roots across European and global credit markets where we have been seeing significant convergence between public and private credit,” commented Hamza Lemssouguer, Founder & CIO of Arini. “We are excited to partner with Lazard’s sector, country, and product bankers across Europe to provide access to financing opportunities, with the goal of generating strong risk-adjusted returns for our investors.”

“The growth of private capital is deeply relevant to our European clients,” said Jean-Louis Girodolle, Lazard’s Co-Head of European Investment Banking. “This commercial agreement embodies Lazard’s commitment to provide clients with innovative products and solutions in this area.”

Mathew Cestar, President of Arini, commented: “Lazard has a rich history serving its European client base over 170+ years. We have built an experienced private credit team that will partner with Lazard’s senior advisory professionals across the region to provide attractive private credit solutions.”

“Our commitment to provide European clients with independent financing advice is enhanced with the addition of Arini’s expertise in fundamental credit investing and strong European pedigree. This is a natural complement to Lazard’s existing capabilities in private credit,” said Cyrus Kapadia, Lazard’s Co-Head of European Investment Banking.

Daniel Garant, Executive Vice President & Global Head, Public Markets at BCI commented: “We believe that positioning Arini’s credit investment capabilities alongside Lazard’s origination creates a highly differentiated and scalable approach to pursue European direct lending opportunities, particularly in the core middle market. BCI is excited to be making this significant long-term investment to increase our exposure to this sector.”

The alliance provides opportunities for Lazard’s advisory client network across EMEA to leverage Arini’s comprehensive sector research coverage and underwriting capabilities. Lazard and Arini have entered into a cooperation and sourcing agreement that sets out our respective obligations pursuant to the alliance. Arini will maintain full autonomy over the investment process and will supplement Lazard’s non-exclusive sourcing activity with its own proprietary deal origination.

ABOUT LAZARD

Founded in 1848, Lazard is one of the world's preeminent financial advisory and asset management firms, with operations in North and South America, Europe, the Middle East, Asia, and Australia. Lazard provides advice on mergers and acquisitions, capital markets and capital solutions, restructuring and liability management, geopolitics, and other strategic matters, as well as asset management and investment solutions to institutions, corporations, governments, partnerships, family offices, and high net worth individuals. For more information, please visit www.lazard.com

ABOUT ARINI

Headquartered in London, Arini Capital Management Limited is a specialized alternative credit manager with a diverse credit investment offering across public and private credit, supported by a highly sophisticated institutional investor base across the globe. Arini was founded in 2021 as an independent alternative credit firm with an approach rooted in fundamental credit analysis, Arini manages $7.9 billion as of February 28, 2025, across a range of strategies, including long/short credit, structured credit, opportunistic credit and direct lending. Arini’s experienced team primarily focuses on European credit markets, which are defined by complex legal and regulatory structures. Learn more at www.arini.com

ABOUT BCI

British Columbia Investment Management Corporation (BCI) is amongst the largest institutional investors in Canada with C$250.4 billion in gross assets under management, as of March 31,2024. Based in Victoria, British Columbia, with offices in Vancouver, New York City, and London, U.K., BCI manages a portfolio of diversified public and private market investments on behalf of its British Columbia pension fund and institutional clients. For more information, visit www.bci.ca

View source version on businesswire.com: https://www.businesswire.com/news/home/20250325087293/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vertex Presents New Data on Benefits of ALYFTREK® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference6.6.2025 18:00:00 CEST | Press release

- Oral presentation on outcomes following treatment with CFTR modulators show that improvements in CFTR function, as measured by lower sweat chloride, correlate with better outcomes for people with cystic fibrosis - - Oral presentation on new post hoc data from randomized, controlled and open-label trials suggest improved quality of life results with ALYFTREK compared to TRIKAFTA® – Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with CFTR modulators and, in particular, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), which is approved in the United States and United Kingdom and is currently under review with health authorities in the EU, Canada, Australia, New Zealand and Switzerland. These data were presented at this year’s European Cystic Fibrosis Society’s (ECFS) 48th European Cystic Fibrosis Conference held June 4-7, 2025, in Milan, Italy. During the conferenc

Andersen Consulting tilføjer dimension med David and Golyat6.6.2025 16:33:00 CEST | Pressemeddelelse

Andersen Consulting udbygger sin globale konsulentkapacitet gennem en samarbejdsaftale med David and Golyat, en filippinsk konsulentvirksomhed inden for digital strategi. Med et stærkt fokus på business intelligence, kundeindsigt og digital first-eksekvering arbejder David and Golyat med kunder på tværs af flere sektorer – herunder regeringer, udviklingsorganisationer og private virksomheder – for at skabe langsigtet værdi gennem datainformerede beslutninger. Miko David, administrerende partner i David and Golyat, siger: "Vi ser frem til samarbejdet med Andersen Consulting, da det er en milepæl i vores vækstforløb. Ved at kombinere vores ekspertise inden for digital strategi og Andersen Consultings globale platform er vi i stand til at levere endnu større værdi til kunder, der navigerer på komplekse markeder." "Dette samarbejde betyder, at vi kan tilføre en ekstra dimension til vores globale konsulentplatform," siger Mark L. Vorsatz, global bestyrelsesformand og administrerende direktø

IBSA Derma at IMCAS Asia 2025: spotlight on the future of aesthetic medicine in the 10th Anniversary Year of NAHYCO® Technology6.6.2025 16:00:00 CEST | Press release

IBSA Derma, the dermoaesthetic division of Swiss company IBSA, will participate in the 18th IMCAS Asia Congress in Bangkok, gathering over 3,000 professionals from across the region to explore the future of aesthetic and regenerative medicine.With the presence in the Congress and a dedicated scientific symposium, the company reaffirms its commitment to advancing bioremodeling approaches and promoting a holistic, science-driven vision of authentic beauty.This year marks a key milestone for IBSA Derma: 10 years of NAHYCO® Technology, a patented innovation in hyaluronic acid science that continues to shape the future of tissue regeneration. IBSA Derma – the dermoaesthetic division of IBSA – once again confirms its leadership in the international aesthetic medicine landscape by participating in the 18th edition of IMCAS Asia, taking place from June 6 to 8 in Bangkok, Thailand. With over 3,000 attendees expected, the event represents a key opportunity for physicians and experts to share the

HistoSonics Completes Enrollment in #HOPE4KIDNEY Trial Evaluating Non-Invasive Histotripsy to Treat Kidney Tumors6.6.2025 14:00:00 CEST | Press release

Pivotal Study Advances to Establish Histotripsy as a Non-Thermal, Surgery-Free Alternative to Destroy and Liquefy Kidney Tumors HistoSonics, Inc., the manufacturer of the Edison® Histotripsy System and novel histotripsy therapy platforms, today announced the completion of patient enrollment in its pivotal #HOPE4KIDNEY trial. This prospective, multi-center, single-arm trial is designed to evaluate the safety and effectiveness of the Edison System in destroying kidney tissue by treating primary solid kidney tumors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606659747/en/ Edison Histotripsy System Procedure for Kidney Tumor Animation The trial enrolled patients with a single, non-metastatic solid kidney mass ≤3 cm, confirmed by imaging and biopsy. Subjects will be followed for five years post-procedure, with evaluations at multiple time points, including 14-day, 30-day, 90-day, 180-day, and annual assessments. The Edison

Norwegian Tech Firm Builds Military Command Center in 24 Hours6.6.2025 13:45:00 CEST | Press release

Norwegian technology provider Cyviz has successfully developed a fully mobile and ballistic-proof command center - designed, configured, and made operational in just 24 hours. The solution was showcased during a military exercise led by the Dutch Ministry of Defence and has already sparked interest from NATO members and civil protection agencies across Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606640770/en/ Cyviz demonstrates rapid deployment capability with a mobile, container-based control room for defense and crisis response Cyviz and its partners constructed the command room inside a 14-ton container designed for transport on standard military vehicles and resistant to machine gun fire. The unit was deployed at a military base in the Netherlands, where Cyviz was tasked with delivering a fully functional command-and-control environment, under strict time constraints and in a high-stakes simulation. "You do

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye